DrugPatentWatch Database Preview

Mission Pharma Company Profile

« Back to Dashboard

What is the competitive landscape for MISSION PHARMA, and when can generic versions of MISSION PHARMA drugs launch?

MISSION PHARMA has fifteen approved drugs.

There are two US patents protecting MISSION PHARMA drugs.

There are ten patent family members on MISSION PHARMA drugs in seven countries and ten supplementary protection certificates in four countries.

Summary for Mission Pharma

International Patents:	10
US Patents:	2
Tradenames:	14
Ingredients:	12
NDAs:	15

Drugs and US Patents for Mission Pharma

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mission Pharma	TINDAMAX	tinidazole	TABLET;ORAL	021618-001	May 17, 2004	AB	RX	Yes	No
Mission Pharmacal Co	CARBINOXAMINE MALEATE	carbinoxamine maleate	TABLET;ORAL	090756-001	May 27, 2011	AA	RX	No	No
Mission Pharma	UROCIT-K	potassium citrate	TABLET, EXTENDED RELEASE;ORAL	019071-001	Aug 30, 1985	AB	RX	Yes	No
Mission Pharma	TEXACORT	hydrocortisone	SOLUTION;TOPICAL	080425-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Non-Orange Book US Patents for Mission Pharma

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
8,449,906	Effervescent compositions comprising phosphonates and methods related thereto

International Patents for Mission Pharma Drugs

Country	Document Number	Estimated Expiration
Spain	2448501
Spain	2380924
Australia	2003219999
European Patent Office	1490024

Supplementary Protection Certificates for Mission Pharma Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C/GB12/028	United Kingdom		PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTERED: UK EU/1/11/734/001-011 20111209
C/GB08/020	United Kingdom		SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/020 GRANTED TO ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. IN RESPECT OF THE PRODUCT RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6346 DATED 05 JANUARY 2011 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 01 JANUARY 2023.
C/GB98/031	United Kingdom		PRODUCT NAME: 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL) BIPHENYL-4-YL)-METHYL)-5-(HYDROXYMETHYL)IMIDAZOLE (LOSARTAN),OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT( LOSARTAN POTASSIUM) AND HYDROCHLOROTHIAZIDE,; REGISTERED: FR 338520.7 19950215; FR 558453.7 19950215; UK 00025/0338 19960412
C0025	Belgium		PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Mission Pharma
• Mission Pharmacal Co